Interest continues to grow rapidly in clinical gene therapy. Although many protocols approved by the US NIH Recombinant Advisory Committee involve the genetic marking of cells to determine, for example, the source of relapse after autologous bone marrow transplantation for certain malignancies (1 ), increasing numbers are concerned with the correction of inherited single-gene disorders.